Faculty Collaboration Database

Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980 Jul;122(1):65-79

Date

07/01/1980

Pubmed ID

6996549

DOI

10.1164/arrd.1980.122.1.65

Scopus ID

2-s2.0-0018904479 (requires institutional sign-in at Scopus site)   156 Citations

Abstract

The pregnant woman with tuberculosis who requires treatment presents a therapeutic dilemma; therefore, we reviewed all available literature on pregnant women treated with isoniazid (INH), ethambutol (EMB), rifampin (RMP), or streptomycin (SM) and report here on the relative safety of these drugs and whether the risk of teratogenesis justifies abortion on medical grounds. Other than the ototoxicity of SM, none of these drugs in normal dosages are proved teratogens to human fetuses. We recommend the use of INH in combination with EMB for a pregnant woman with tuberculosis, if the disease is not extensive. If a third drug is warranted, then RMP could be added. Because of its ototoxicity, SM should not be used, unless RMP is contraindicated or proves unsatisfactory. Routine therapeutic abortion is not medically indicated for a pregnant woman who is taking first-line antituberculosis drugs.

Author List

Snider DE Jr, Layde PM, Johnson MW, Lyle MA

MESH terms used to index this publication - Major topics in bold

Abnormalities, Drug-Induced
Adolescent
Adult
Antitubercular Agents
Ethambutol
Female
Hearing Disorders
Humans
Isoniazid
Limb Deformities, Congenital
Pregnancy
Pregnancy Complications, Infectious
Rifampin
Streptomycin
Tuberculosis, Pulmonary